Plasma cell leukemia: Detailed studies and response to therapy

Shaw, Michael; Twele, Thomas W.; Nordquist, Robert E.

doi:10.1002/1097-0142(197403)33:3<619::aid-cncr2820330305>3.0.co;2-0

Cited by 23 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Shaw et al16 obtained a good partial response following a regimen of cyclophosphamide, vincristine, cytosine arabinoside and prednisolone (COAP) and later high dosage melphalan and prednisolone.Their patient survived for 13 months and Lishner et al8 using COAP achieved a survival of 22 months.Cyclophosphamide12'14 alone, or in combination with prednisolone12'13 has effected survival of up to 4 years and in one case doxorubicin successfully controlled subcutaneous tumour nodules. In our patient general debility precluded this being used.…”

mentioning

confidence: 99%

Survival of twenty-two months in a patient with primary plasma cell leukaemia treated with melphalan and prednisolone

Walker

Kaczmarski²

1988

Postgraduate Medical Journal

View full text Add to dashboard Cite

Summary In the majority of cases plasma cell leukaemia is a rapidly fatal disease with a mean survival time of five months. There have been reports of increased survival using various regimens of chemotherapy although most cases eventually relapse. We describe a patient with primary plasma cell leukaemia who responded to a combination of oral melphalan and prednisolone with control of the disease in the bone marrow but relapsed with extramedullary disease in the central nervous system and testes, and died 22 months after diagnosis. Melphalan poorly penetrates the central nervous system and its testicular penetration is unknown.

show abstract

mentioning

confidence: 99%

Survival of twenty-two months in a patient with primary plasma cell leukaemia treated with melphalan and prednisolone

Walker

Kaczmarski²

1988

Postgraduate Medical Journal

View full text Add to dashboard Cite

show abstract

“…Skadberg et al (32) reported the sudden death of a patient with multiple myeloma and cardiac amyloidosis who developed complete heart block. Plasma cell leukemia may arise either as a terminal manifestation in an individual with an established diagnosis of myeloma or as a de novo acute leukemia and typically follows the fulminant course characteristic of the other acute leukemias (3)(4)(5)(6)(7)33,34).…”

Section: Discussionmentioning

confidence: 99%

Sudden Unexpected Death Due to a Previously Undiagnosed Plasma Cell Dyscrasia

Hamilton¹,

Wolf

2008

Journal of Forensic Sciences

View full text Add to dashboard Cite

The plasma cell dyscrasias are a diverse group of disorders characterized by the production of a clonal paraprotein. Sudden death is a recognized complication of the plasma cell dyscrasias, most commonly in individuals with cardiac involvement by amyloidosis. However, the current forensic literature has no reported cases in which sudden death resulted from complications of a plasma cell dyscrasia that was first diagnosed by postmortem histologic examination. We present the case of a woman whose sudden and unexpected death resulted from a seizure. Postmortem examination revealed no evidence of trauma or a grossly identifiable natural disease process that would have accounted for her death. However, microscopic and immunohistologic studies revealed a previously undiagnosed plasma cell dyscrasia, the clonality of which was determined by immunohistochemical studies for immunoglobulin light chains, that was not associated with amyloid deposition. This case elucidates a previously unrecognized cause of sudden unexpected death and illustrates the importance of microscopic studies in selected cases examined in medical examiner/coroner offices.

show abstract

“…Median survival was 2 months, with only 3 patients living at l year [9]. Various other series have reported a median survival of 6 months [3,6,10,11].…”

Section: Discussionmentioning

confidence: 99%

Ifosfamide in plasma cell leukemia: A report of two cases and review of the literature

et al. 1992

View full text Add to dashboard Cite

We report two patients with primary plasma cell leukemia (PLC) treated with a single agent, ifosfamide. One patient had a total disappearance of plasma cells (PC) from the peripheral blood and the bone marrow and disappearance of the myeloma protein, is disease free 8 months after completion of treatment, and alive 14 months after diagnosis. The second patient had a partial response with persistence of plasma cells in the bone marrow lasting 7 months, after which she had a frank relapse of the disease. We suggest that ifosfamide may be an active agent in plasma cell malignancies and needs further evaluation in multiple myeloma.

show abstract

Plasma cell leukemia: Detailed studies and response to therapy

Cited by 23 publications

References 12 publications

Survival of twenty-two months in a patient with primary plasma cell leukaemia treated with melphalan and prednisolone

Survival of twenty-two months in a patient with primary plasma cell leukaemia treated with melphalan and prednisolone

Sudden Unexpected Death Due to a Previously Undiagnosed Plasma Cell Dyscrasia

Ifosfamide in plasma cell leukemia: A report of two cases and review of the literature

Contact Info

Product

Resources

About